Fierce Biotech Names AbCellera a “Fierce 15” Company of 2020

VANCOUVER, British Columbia, September 28, 2020 — AbCellera today announced that it has been named by Fierce Biotech as one of 2020’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Every year Fierce Biotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers, and a competitive market position.

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The 2020 Fierce 15 comes at a time when the world is focused on a pandemic, but even as coronavirus remains a threat, patients with cancer, rare diseases, and other disorders still need treatment, Fierce Biotech Senior Editor Ben Adams said. “This year, we’ve chosen from a diverse range of those fighting COVID, as well as those fighting longer term plagues against our biology,” said Adams.

AbCellera’s full-stack, AI-powered technology sources, searches, decodes and analyzes natural immune responses to identify antibodies for next-generation therapeutics. Over the past two years, under DARPA’s Pandemic Prevention Platform (P3) program, the company tailored its technology for rapid pandemic response, which contributed to the world’s first COVID-19 clinical trial for a potential monoclonal antibody treatment

LY-CoV555 is a neutralizing antibody against SARS-CoV-2 that emerged from AbCellera’s collaboration with Eli Lilly and was discovered in collaboration with AbCellera and scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. Starting from a single blood sample obtained from a convalescent patient, LY-CoV555 was identified within three weeks and it was advanced into clinical testing in 90 days and is currently in Phase 3 clinical trials.

“Our response to COVID-19 is a time-compressed example of why AbCellera exists – to build and bring together the teams and technologies needed to solve the toughest problems in drug development,” said Carl Hansen, Ph.D., CEO of AbCellera. “Drug development takes too long, fails too often, and costs too much. To solve this, we’re building a modern operating system for drug developers to ensure the best science is translated quickly into new therapies for patients.”

AbCellera’s antibody discovery platform integrates patented and proprietary technologies to advance the development of new biological modalities, from monoclonal, multi-specific, and single-domain antibodies, to bioconjugates, gene-encoded biologics, and cell therapies. For the company’s partners, AbCellera has successfully completed more than 55 programs, delivering high-quality antibody drug candidates for a wide variety of drug targets, including historically challenging multi-pass membrane protein targets, such as GPCRs and ion channels. The company has generated lead therapeutic antibody candidates for unmet needs in various disease areas including cancer, immuno-oncology, neurodegeneration, pain, fibrosis, and metabolic disorders.

About Fierce Biotech

Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.  

About AbCellera Biologics Inc.

AbCellera is a privately held technology company with an antibody discovery platform that searches and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. AbCellera’s technology, which combines high-throughput microfluidics, hyper-scale data science, machine learning, bioinformatics, and genomics, identifies new antibody drug candidates and aims to reduce the time it takes to bring treatments to the clinic. AbCellera’s partners include leading biotechnology companies, global health organizations, and top 10 biopharmaceutical companies. For more information, visit abcellera.com.    

Inquiries:

Jessica Yingling; media@abcellera.com, +1.236.521.6774 (AbCellera Media)

Kevin Heyries; bd@abcellera.com, +1.604.559.9005 (AbCellera Business Development)

AbCellera Wins Fast Company’s Innovative Team of the Year Award and Is Named to the 2020 Best Workplaces for Innovators List

VANCOUVER, British Columbia – AbCellera has been named to Fast Company’s 2020 list of Best Workplaces for Innovators and awarded the Innovative Team of the Year.

Fast Company’s list of Best Workplaces for Innovators honors companies that “share a commitment to unlocking the potential of creative individuals and diverse teams.” AbCellera’s team, which includes data scientists, engineers, programmers and scientists, removes bottlenecks in drug discovery and works collaboratively with biotech and pharma companies to bring new therapies to patients. By innovating at every step, AbCellera’s team and technology are able to quickly scan, decode, and analyze antibodies from natural immune systems to discover antibodies that can be developed into novel treatments.

AbCellera’s Pandemic Prevention Platform (P3) team was named the 2020 Innovative Team of the Year, which honors the team “that went above and beyond to achieve a significant breakthrough.” The P3 team was recognized for developing antibody countermeasures against COVID-19, including LY-CoV555, the fastest therapeutic antibody molecule ever developed. Together with its partners, AbCellera’s P3 team moved LY-CoV555 from first screen to clinical testing in 90 days and was the world’s first human study of a potential antibody treatment for COVID-19.

Visit Fast Company for the full list of Best Workplaces for Innovators and more on the Innovative Team of the Year.

AbCellera Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020

VANCOUVER, British Columbia – AbCellera, the antibody company, has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2020 for its drug discovery platform that can search and analyze natural immune systems to deliver best-in-class antibody drugs. By innovating at every step of the discovery process, AbCellera’s team has repeatedly proven its ability to unlock novel targets, including those previously considered ‘undruggable’ due to technical challenges associated with antibody generation. AbCellera is transforming the field of biologics, generating first-in-class drugs through partnerships with pharma and biotech companies and reducing timelines to advance new programs towards the clinic. 

Fast Company’s list honors the businesses making the most profound impact on both industry and society, showcasing a variety of ways to thrive in today’s fast-changing world. An example of how AbCellera’s innovative approach is being used to address real-world challenges is its response to the current coronavirus (SARS-CoV-2) outbreak that causes COVID-19. AbCellera is leading a team of industry experts in the Pandemic Prevention Platform (P3) program, a DARPA initiative to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen. As part of this program, AbCellera is working on discovering SARS-CoV-2-neutralizing antibodies that could ultimately be deployed to stop transmission of the coronavirus that causes COVID-19.  

“The big problem we set out to solve is clear: we need to bring better treatments to patients faster,” said Dr. Carl Hansen, CEO of AbCellera. “AbCellera was founded on the belief that the solution to this problem lies in technology.  We innovate and integrate state-of-the-art technologies across multiple disciplines, from AI and genomics to big data and single cell analysis, to build a platform that can tackle the toughest drug discovery challenges.” 

Natural immune responses generate billions of potential antibodies and are the best source for discovery of new antibody therapeutics.  Leveraging big data and a suite of proprietary technologies compatible with any natural immune source, AbCellera’s discovery campaigns are performed at a scale that leaves no stone unturned, resulting in large panels of curated antibody candidates. AbCellera’s core technology is a high-throughput microfluidic platform that uses miniaturized assays to screen antibodies from millions of individual immune cells from any species, including directly from human donors. Combined with Celium™, AbCellera’s powerful antibody visualization and exploration software, the platform can search and analyze natural immune systems with unmatched speed and depth to deliver diverse sets of high-quality antibody drug candidates. Through collaborations with its partners, AbCellera applies its technology to generate therapeutic candidates for unmet needs in a wide range of disease areas including, cancer, neurodegeneration, pain, fibrosis, and metabolic disorders. 

“At a time of increasing global volatility, this year’s list showcases the resilience and optimism of businesses across the world. These companies are applying creativity to solve challenges within their industries and far beyond,” said Fast Company senior editor Amy Farley, who oversaw the issue with deputy editor David Lidsky. 

About AbCellera Biologics Inc.

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a unique combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, deep computation, artificial intelligence, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. For more information, visit abcellera.com

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Since 2011, Fast Company has received some of the most prestigious editorial and design accolades, including the American Society of Magazine Editors (ASME) National Magazine Award for “Magazine of the Year,” Adweek’s Hot List for “Hottest Business Publication,” and six gold medals and 10 silver medals from the Society of Publication Designers. The editor-in-chief is Stephanie Mehta and the publisher is Amanda Smith. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.

 

Approved for Public Release, Distribution Unlimited

 

AbCellera Contacts: 

Jessica Yingling, Ph.D., media@abcellera.com +1.858.344.8091 (Media)

Kevin Heyries, Ph.D., bd@abcellera.com, +1.604.559.9005 (Business Development)

 

AbCellera named one of Canada’s Top Growing Companies

AbCellera, a biotech focusing on the discovery of therapeutic antibodies, is one of Vancouver’s top 10 fastest growing companies, according to the Globe and Mail’s list of Canada’s Top Growing Companies. The Report on Business ranks Canadian companies based on three-year revenue growth. 

“AbCellera is on a trajectory to become a Canadian anchor company. Greater Vancouver is home to world-class research universities and one of North America’s leading pool of tech talent,” said Dr. Carl Hansen, CEO of AbCellera. “It’s a great place to build a biotech.”

AbCellera was founded in 2012 as a spin-off from the University of British Columbia (UBC), where Dr. Hansen was a faculty member from 2005 to 2019, and recently resigned at the rank of Full Professor. The company has pioneered a technology platform integrating microfluidics, next-generation DNA sequencing, machine learning and artificial intelligence to uncover molecules naturally produced by the immune system that can be turned into effective therapeutics. These molecules, called antibodies, are nature’s defense to fight diseases, and constitute the fastest growing class of drugs to treat indications like cancer, arthritis, pain and infections.

After bootstrapping its initial growth from customer revenue, AbCellera moved into a 21,000 sq ft custom lab facility last year to accommodate its expanding activities. The company’s diverse and interdisciplinary team of biological scientists, engineers, data scientists, AI specialists, and UX designers, has nearly doubled over the past year. With over 100 employees, AbCellera continues to hire to keep up with the company’s thriving business and tech development. 

Last year, AbCellera closed a US$10 million Series A financing led by DCVC Bio, a venture capital firm based in San Francisco. It continues to gain momentum, announcing several strategic partnerships with big pharma and large biotechs, and three-year revenue growth of 927%. In addition to discovering next-generation therapies, AbCellera has leveraged its technologies to improve global health, receiving a US$4.8 million award from the Bill & Melinda Gates Foundation to advance vaccine research, and landing a US$30 million contract from the US Department of Advanced Research Projects Agency (DARPA) to develop a platform that can generate antibody countermeasures to halt a pandemic within 60 days. 

In June 2019, AbCellera was awarded the BC Technology Impact Award for Company of the Year – Scale Success, being recognized alongside companies like SAP, Microsoft, and Clio. And earlier this month, the team welcomed local tech veteran Andrew Booth as CFO to guide the company through its next stage of growth.  

The full list of Canada’s Top Growing Companies 2019 winners, and accompanying editorial coverage, is published in the October issue of Report on Business magazine.

LifeSciences BC Growth Stage Company of the Year Awarded to AbCellera

Vancouver, Canada (February 19th, 2018)LifeSciences BC has named AbCellera the LSBC Growth Stage Company of the Year. This is one of several awards presented annually to distinguished organizations and leaders in the life sciences field in British Columbia.

AbCellera was founded in 2012 as a spin-off company from The University of British Columbia. Fuelled primarily by revenue from partnerships with pharmaceutical and biotechnology companies, AbCellera has grown from 10 to 45 employees over the past three years and recently announced its 25th partnered discovery program. The development of its state-of-the-art, proprietary single-cell antibody screening platform for the discovery of therapeutic monoclonal antibodies has resulted in a game-changing technology capable of unlocking the most challenging therapeutic programs.

The Vancouver-based startup is amongst the 20th Annual LifeSciences BC Award recipients, which include:

  • Genome BC Award for Scientific Excellence – Dr. Sally Aitken
  • Michael Smith Foundation for Health Research – Aubrey J. Tingle Award – Dr. David Huntsman
  • Milton Wong Award for Leadership – Dr. Michael Abrams
  • Growth Stage Life Sciences Company of the Year – AbCellera Biologics Inc.
  • Strategic Life Sciences Partner of the Year Award – Starfish Medical Inc.
  • Medtech Company of the Year – Redlen Technologies Inc.
  • Growth Stage Medtech Company of the Year – bioLytical Laboratories Inc.
  • Deal of the Year Award – Zymeworks Inc.
  • LifeSciences Company of the Year – Aurinia Pharmaceutical Inc.
  • Dr. Don Rix Award for Lifetime Achievement – Drs. Allen & Connie Eaves

AbCellera’s CEO Carl Hansen commented, “It is a particular honour to be counted in this year’s outstanding line-up of winners. Without exception, this year’s awardees embody the scientific excellence and bold entrepreneurial spirit that defines the best of BC’s life sciences sector. From Aurinia’s run to clinical success, to the trailblazing IPO and continued dealmaking of Zymeworks, to the rare marriage of strong scientific and business leadership of Connie & Allen Eaves, the achievements of this group demonstrate the quality of basic science and innovation in British Columbia.  AbCellera is grateful for this recognition and is committed to doing its part in building a vibrant and globally competitive life sciences sector in BC.”

The 2018 LifeSciences BC award winners will be recognized at this year’s annual dinner presented by FARRIS, held on April 19, 2018 at the Fairmont Hotel Vancouver.

About LifeSciences BC

LifeSciences BC is a not-for-profit, non-government, industry association that supports and represents the life sciences community of British Columbia through leadership, facilitation of investment and partnering, advocacy, and promotion of our world-class science and industry.

Life sciences sectors, from biopharmaceuticals and medical technology, to digital health and medical devices, are integrated into our organization and all that we do, ensuring that no life sciences sector is working in isolation — and that all sectors come together in a comprehensive, complementary and coordinated fashion.

About AbCellera Biologics Inc.

AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans.

Media Contact

Kevin Heyries
Telephone: 604.559.9005
Email: media@abcellera.com

AbCellera Named to 2016 Life Science Emerging Rockets List of High Growth Companies

Vancouver, Canada (March 2, 2016) – Authored by technology consulting firm Rocket Builders for 14 consecutive years, the list identifies tech companies in British Columbia (BC) that are “best positioned to capitalize on technology trends that will lead them to faster growth than their peers”.

“We believe next-generation antibody therapies have the potential to significantly impact the future of medicine and human health,” says Dr. Carl Hansen, President and CEO of AbCellera. “We’ve had a number of innovative partnerships with global pharma and biotech organizations in recent months and are excited to be recognized among BC’s high growth companies.”

The 2016 Life Science Emerging Rockets list includes nine other technology companies in BC, and can be viewed at http://www.readytorocket.com/2016/03/2016-life-science-emerging-rockets.html.

About AbCellera Biologics Inc. 
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.

AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans. 

Contact 
Kevin Heyries 
Telephone: 604.827.4151 
Email: media@abcellera.com

About Ready to Rocket 
Ready to Rocket is a unique business recognition list that profiles technology companies with the greatest potential for growth. Each year, based on analysis of trends, Rocket Builders identifies the top private companies that are best positioned to capitalize on these trends to achieve growth. This selection methodology has been an accurate predictor of investment and business success with past “Ready to Rocket” companies. www.readytorocket.com 

Trademark Notice 
“Ready to Rocket” is a trademark of Rocket Builders, a respected management consulting firm servicing the technology industry.